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Species-specific and pathotype-specific binding of bacteria to zymogen
granule membrane glycoprotein 2 (GP2)
Abstract
With interest we read the paper by Juste et al 1 proposing the amount of zymogen-granule membrane
glycoprotein 2 (GP2) on the surface of intestinal bacteria as a Crohn's disease (CD) marker. Indeed, a
decreased GP2 level was found on microbes in patients with CD as compared to those of healthy controls.
GP2 is a homologue to the urinary Tamm–Horsefall protein demonstrating an antimicrobial function by
binding type 1-fimbriated uropathogenic Escherichia coli (UPEC). Likewise, GP2 seems to interact with
intestinal bacteria as a specific receptor of bacterial type-1 fimbriae (FimH) on intestinal microfold cells that
are partaking in immune responses against such microbes.2 GP2 is overexpressed in the inflamed intestine of
patients with CD and has an immunomodulating role in innate and acquired immune responses.3
,4Interestingly, GP2 was identified as autoantigen of pancreatic antibodies in CD.4 Altogether, these findings
indicate two major GP2 sources (pancreatic/intestinal) and support a role for GP2 in the interaction between
the immune system and intestinal microbiota.3 Thus, loss of tolerance to GP2 could play a role in CD's
pathophysiology supposed to be exacerbated by preceding intestinal infections. In general, the findings by
Juste et al 1 may be explained by a lower pancreatic GP2 secretion, an impaired GP2 binding to bacteria, or by
a higher prevalence of bacteria with poor or no GP2 binding in patients with CD.
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response before measuring any drug or
antidrug antibody levels. Without the
correct context of loss of response, inter-
pretation of drug and antidrug antibody
levels would be inappropriate, especially
so when drug levels are found to be of
therapeutic levels. When properly
deﬁned, customised treatment based on
therapeutic drug monitoring will avoid
unhelpful dose-intensiﬁcation of biologics
for some patients and be cost-efﬁcient
from a macro-economic level.
Nevertheless, I would like to congratu-
late the authors for undertaking the task
of demonstrating the cost effectiveness of
individualised biologic therapy for
patients with complicated CD in the era
of personalised medicine.
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With interest we read the paper by Juste
et al1 proposing the amount of zymogen-
granule membrane glycoprotein 2 (GP2)
on the surface of intestinal bacteria as a
Crohn’s disease (CD) marker. Indeed, a
decreased GP2 level was found on
microbes in patients with CD as compared
to those of healthy controls. GP2 is a
homologue to the urinary Tamm–
Horsefall protein demonstrating an anti-
microbial function by binding type
1-ﬁmbriated uropathogenic Escherichia
coli (UPEC). Likewise, GP2 seems to
interact with intestinal bacteria as a spe-
ciﬁc receptor of bacterial type-1 ﬁmbriae
(FimH) on intestinal microfold cells that
are partaking in immune responses against
such microbes.2 GP2 is overexpressed in
the inﬂamed intestine of patients with CD
and has an immunomodulating role in
innate and acquired immune responses.3 4
Interestingly, GP2 was identiﬁed as auto-
antigen of pancreatic antibodies in CD.4
Altogether, these ﬁndings indicate two
major GP2 sources (pancreatic/intestinal)
and support a role for GP2 in the inter-
action between the immune system and
intestinal microbiota.3 Thus, loss of
Figure 1 Binding of Escherichia coli pathotypes to GP2. Human recombinant GP2 expressed
in Sf9 cells were immobilised on 96-well plates with anti-FimH antibodies used as positive, or
human serum albumin as negative controls. After incubation of bacterial suspensions for 2 h
followed by subsequent washing, bound bacteria were stained with a ﬂuorescent dye and
counted with an automated ﬂuorescence interpretation system (Aklides, Medipan, Dahlewitz,
Germany). Bound bacteria are represented as bacteria per image (bpi, image=0.61 mm2). UPEC:
human uropathogenic E. coli (n=24), HFEC: human intestinal commensal (fecal) E. coli (n=24),
ETEC: human enterotoxigenic E. coli (n=24), EPEC: human enteropathogenic E. coli (n=24),
SAEC: sepsis-associated human E. coli isolated from sepsis patients (n=24), EAEC: human
enteroaggregative E. coli (n=17), AFEC: chicken intestinal commensal (avian fecal) E. coli (n=24),
CAEC: Crohn’s disease-associated E. coli isolated from patients with Crohn’s disease (n=20),
Salmonella: Salmonella serovar (n=24), Klebsiella: Klebsiella pneumoniae (n=12), Proteus: Proteus
mirabilis (n=12), Buttiauxella (n=6), Pantoea: Pantoea agglomerans (n=5), Raoultella: Raoultella
ornithinolytica (n=7), Serratia: Serratia fonticola/liquefaciens (n=6), and methillicin-resistant
Staphylococcus aureus: MRSA (n=24). Data are displayed as bpi in box-and-whisker plots with far
out values, deﬁned as values that are smaller than the lower quartile minus 3 times the IQR, or
larger than the upper quartile plus 3 times the IQR, displayed as solid triangles. Posthoc analysis,
p<0.05 for the following comparisons: UPEC: ETEC, EAEC, Salmonella, Buttiauxella, Pantoea,
Serratia, MRSA. HFEC: ETEC, EAEC, Salmonella, Proteus, Buttiauxella, Pantoea, Serratia, MRSA.
ETEC: UPEC, HFEC, EPEC, SAEC, AFEC, CAEC, Salmonella, Klebsiella, Buttiauxella, Pantoea,
MRSA. EPEC: ETEC, EAEC, Salmonella, Proteus, Buttiauxella, Pantoea, Serratia, MRSA. SAEC:
ETEC, EAEC, Salmonella, Buttiauxella, Pantoea, Serratia, MRSA. EAEC: UPEC, HFEC, EPEC, SAEC,
AFEC, CAEC, Salmonella, Klebsiella, Buttiauxella, Pantoea. AFEC: ETEC, EAEC, Salmonella,
Buttiauxella, Pantoea, Serratia, MRSA. CAEC: ETEC, EAEC, Salmonella, Buttiauxella, Pantoea,
Serratia, MRSA. Salmonella: UPEC, HFEC, ETEC, EPEC, SAEC, EAEC, AFEC, CAEC, Klebsiella,
Proteus, Buttiauxella, Pantoea, Raoultella, Serratia, MRSA. Klebsiella: ETEC, EAEC, Salmonella,
Buttiauxella, Pantoea, Serratia, MRSA. Proteus: HFEC, EPEC, Salmonella, Buttiauxella, Pantoea,
MRSA. Buttiauxella: UPEC, HFEC, ETEC, EPEC, SAEC, EAEC, AFEC, CAEC, Salmonella, Klebsiella,
Proteus, Raoultella. Pantoea: UPEC, HFEC, ETEC, EPEC, SAEC, EAEC, AFEC, CAEC, Salmonella,
Klebsiella, Proteus, Raoultella. Raoultella: Salmonella, Buttiauxella, Pantoea, MRSA. Serratia:
UPEC, HFEC, EPEC, SAEC, AFEC, CAEC, Salmonella, Klebsiella. MRSA: UPEC, HFEC, ETEC, EPEC,
SAEC, AFEC, CAEC, Salmonella, Klebsiella, Proteus, Raoultella.
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tolerance to GP2 could play a role in
CD’s pathophysiology supposed to be
exacerbated by preceding intestinal infec-
tions. In general, the ﬁndings by Juste
et al1 may be explained by a lower pan-
creatic GP2 secretion, an impaired GP2
binding to bacteria, or by a higher preva-
lence of bacteria with poor or no GP2
binding in patients with CD.
We have a longstanding interest in GP2’s
intestinal function and, therefore, we eval-
uated GP2 as receptor for intestinal
bacterial pathotypes by testing the binding
of 284 bacteria in a novel binding assay.5
These bacteria were of 8 E. coli patho-
types, 8 Salmonella serovars, 6 other
Enterobacteriaceae genera (Klebsiella,
Proteus, Buttiauxella, Pantoea, Raoultella,
Serratia), and methicillin-resistant
Staphylococcus aureus (MRSA) (ﬁgure 1).
Binding rates of isolates ranged from 0 to
2117 bacteria per image (bpi), and
Salmonella isolates exhibited the signiﬁ-
cantly highest binding to GP2; whereas,
Proteus, Buttiauxella, Pantoea, Raoultella,
Serratia and MRSA isolates demonstrated
low binding (Kruskal–Wallis test,
p<0.000001). E. coli pathotypes and
Klebsiella expressed medium binding rates.
CD-associated E. coli (CAEC) demon-
strated no signiﬁcantly different binding to
GP2 than human commensal (fecal) E. coli
(HFEC); sepsis-associated E. coli; UPEC,
enteropathogenic E. coli (EPEC) or chicken
commensal (avian fecal) E. coli, but a
higher binding than enterotoxigenic E. coli
and human enteroaggregative E. coli
(posthoc analysis, p<0.05, respectively).
Nine out of 10 ﬁmH-negative isolates
showed low binding to GP2, and
one HFEC isolate a high binding rate
(473 bpi). GP2 binding of Salmonella,
E. coli and other bacterial groups
was mannose-sensitive and not glucose-
sensitive as shown by inhibition experi-
ments proving a GP2-FimH interaction.
To investigate the interaction between
FimH-protein and GP2 at a molecular
level, we sequenced ﬁmH genes of 48
E. coli isolates: six isolates of each patho-
type including two isolates not binding
to GP2, two isolates showing medium
and two isolates showing strong binding.
Thus, we deﬁned 23 different FimH-
amino acid sequences. Though there was
no speciﬁc FimH-amino acid sequence
variation for an E. coli pathotype, FimH
sequences seem to correlate with the
strength of binding of GP2 to bacteria
(ﬁgure 2). Additionally, bacterial binding
to GP2 correlated signiﬁcantly with that
to anti-FimH antibodies, indicating that
FimH-expression levels are associated
with GP2 binding (p<0.0001, see online
supplementary data).
We conclude that GP2 is an intestinal
epithelial receptor interacting with dis-
tinct FimH-positive bacteria. This inter-
action can be modulated by pancreatic
GP2 secreted together with zymogens
into the intestine. GP2 binding is select-
ive for bacterial species and pathotypes
and, thus, may determine immune
responses to the intestinal microbiota.
CAEC do not differ in their binding
from most E. coli isolates supporting the
Figure 2 Correlation between the FimH-amino acid sequences and binding to GP2. E. coli
isolates with different binding characteristics to GP2 (n=48) were sequenced and clustered
according to the FimH-amino acid sequences. Data on each isolate are: isolate collection number,
pathotype, binding to GP2 (low adhesion: <20 bpi; medium adhesion: 50–100 bpi; high
adhesion: >300 bpi). UPEC: human uropathogenic E. coli, HFEC: human intestinal (fecal)
commensal E. coli, ETEC: human enterotoxigenic E. coli, EPEC: human enteropathogenic E. coli,
SAEC: sepsis-associated human E. coli isolated from patients with sepsis, EAEC: human
enteroaggregative E. coli, AFEC: chicken intestinal (avian fecal) commensal E. coli, CAEC: Crohn’s
disease-associated human intestinal E. coli from patients with Crohn’s disease.
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assumptions that other bacteria with low
GP2 binding are more abundant in CD,
or the GP2 interaction with CAEC is
impaired.
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The effect of exercise and diet
on gut microbial diversity
We have read with great interest the study
by Clarke et al1 who in a very elegant and
sophisticated manner documented the
increase in gut microbial diversity in associ-
ation with exercise and dietary extremes in
professional rugby players. The observed
microbial shifts were accompanied by lower
inﬂammatory and healthier metabolic pro-
ﬁles among athletes. Signiﬁcantly higher
proportions of the genus Akkermansia
muciniphila in athletes as well as in low
Body Mass Index control group were
found. As previously shown, the presence
of these bacteria in the human GI tract has
been associated with improved metabolic
proﬁles, possibly due to enhanced barrier
function. However, from the study of
Clarke et al it is difﬁcult to draw the con-
clusion and assess the impact of exercise
per se from dietary inﬂuences in groups
studied for their gut microbial diversity. As
the alterations of the microbial diversity
have already been linked to changes in
dietary habits, it is important to address an
important issue, which is the reported high
prevalence of GI presentations among pro-
fessional athletes. Endurance training has
been associated with reduced GI blood
ﬂow, tissue hyperthermia and hypoxia
leading to possible alterations of microbiota
and GI barrier. As documented in a well-
designed and randomised, double-blinded,
placebo-controlled trial, probiotic supple-
mentation affected markers of intestinal
barrier, oxidation and inﬂammation in
trained men. Lamprecht et al have shown
that a 14-week period of supplementation
with multi-species probiotics in trained
men led to normalisation of stool zonulin
concentrations (a marker indicating
enhanced gut permeability) as compared
with the placebo group. The researchers
found no effect of exercise on tumour
necrosis factor-α serum concentrations.2
Other studies with high endurance athletes
documented beneﬁcial effects of dietary
interventions on improvements in cytokines
and immune-marker panels, positive effects
on redox biology and lessening of GI symp-
toms. As implicated in the study by Clarke
et al, the gut microbial diversity may be
viewed as a new biomarker or indicator of
health. However, Wills et al3 in their recent
prospective study using next-generation
sequencing for examining the faecal micro-
biota composition in patients with IBD
during a quiescent disease phase and a sub-
sequent exacerbation could not demon-
strate general changes in microbial
composition or diversity in both groups
studied. Of importance, a large increase in
relative abundance of Bacteroides fragilis or
Akkermansia muciniphila during active
phase of disease in some of patients was
reported.3 Other studies document that
prolonged strenuous exercise expands the
population of developmentally early stem
cells in bone marrow and mobilises them
into peripheral blood (personal communi-
cation, Dr Ratajczak, University of
Lousiville, USA).4 The precise mechanism
of this phenomenon is not known;
however, it could play an important role in
tissue/organ rejuvenation after strenuous
exercise. Our group has documented an
increase in mobilisation of stem and pro-
genitor cells into peripheral blood in
patients with active IBD.5 It is difﬁcult to
exclude that these health effects are at least
in part mediated by gut derived bacterial
lipopolysaccharides (endotoxins), which
enter the general circulation due to
impaired gut barrier integrity and increased
intestinal permeability—factors which
could be considered more important health
determinants than microbial composition
itself. It would be very tempting to address
the role of intestinal barrier (eg, by measur-
ing intestinal markers such as intestinal-fatty
acid binding protein or zonulin) or to
measure the levels of serum endotoxin in
future studies investigating the effect of
exercise and diet on gut microbiota.
Observations that antibiotic treatment
abolishes stem/progenitor cell mobilisation
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